Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Summary by Hastings Tribune
RAHWAY, N.J.--(BUSINESS WIRE)--Feb 19, 2026-

2 Articles

Hastings TribuneHastings Tribune
Reposted by
HealthTech HotSpotHealthTech HotSpot
Center

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

RAHWAY, N.J.--(BUSINESS WIRE)--Feb 19, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Thursday, February 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Rahway icon

Rahway

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal